Evidence & regulatory context
- Mechanism
- Not recorded
- Target
- Not recorded
- Injury models
- Chemical/toxin
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- Not recorded
- ChEMBL record
- Not recorded
- ChEMBL max phase
- Not recorded
- Synonyms
- Not recorded
- Note
- Not recorded
Clinical trials 0
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
No linked human trial in this dataset.
Preclinical evidence 1
1 studies reported at therapy level; 1 evidence entries itemised.
MouseChemical/toxinC57BL/6Malen = 16 mice per group in four groups; n = 6 for LDH, n = 8 for…Oral, suspended in 0.5 per cent sodium carboxymethyl cellulose50 mg/kg or 100 mg/kg orally in vivo; 1.25, 2.5, 5 and 10 m…Oral latifolin started 4 days before the doxorubicin injection, which was given…
Model: Doxorubicin-induced cardiotoxicity, single intraperitoneal dose of doxorubicin 20 mg/kg on day 5
Latifolin at 100 mg/kg significantly reduced cardiac LDH, improved left ventricular ejection fraction and fractional shortening, and preserved myocardial architecture. It decreased myocardial iNOS and CD86 expression and increased CD206, IL-10 and IL-4R. In cultured peritoneal macrophages latifolin…
Extraction: extract · Supplied extraction confidence: 0.92. Machine-extracted fields require source verification.